跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
謝 名宗
Doctor
內科部
電子郵件
csgigo
gmail
com
h-index
57
引文
5
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2020
2025
每年研究成果
概覽
指紋
網路
研究成果
(12)
類似的個人檔案
(12)
指紋
查看啟用 Ming-Tsung Hsieh 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Helicobacter pylori
66%
Immune Checkpoint Inhibitor
45%
Tetracycline
33%
Amoxicillin
33%
Lenvatinib
33%
Nivolumab
33%
Pembrolizumab
33%
Chemotherapy
33%
Sorafenib
33%
Tranexamic Acid
33%
Comorbidity
33%
Programmed Death 1 Receptor
33%
Peptic Ulcer Bleeding
33%
Blood Stasis
33%
Metronidazole
18%
Drug Resistance
18%
Combination Therapy
18%
Overall Survival
16%
Protein Tyrosine Kinase Inhibitor
12%
Adverse Event
11%
Infection
11%
Ulcer
10%
Bleeding
10%
Tumor Thrombus
8%
Clinical Trial
8%
Prospective Study
7%
Levofloxacin
7%
Clarithromycin
7%
Treatment Group
6%
Progression Free Survival
5%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Immune Checkpoint Inhibitor
49%
Adverse Event
40%
Endoscopic Retrograde Cholangiopancreatography
33%
Endoscopic Hemostasis
33%
Computer Assisted Tomography
33%
Nivolumab
33%
Common Bile Duct Stone
33%
Immunotherapy
33%
Pembrolizumab
33%
Peptic Ulcer Bleeding
33%
Hepatic Arterial Infusion
33%
Tranexamic Acid
33%
Endoscopic Ultrasound
33%
Sucralfate
33%
Hazard Ratio
26%
Overall Survival
23%
Progression Free Survival
17%
Treatment Response
10%
Bleeding
10%
Ulcer
10%
Tumor Thrombus
8%
Health Care Cost
8%
Treatment Group
6%
Endoscopy
6%
Diseases
6%
Combination Therapy
5%
Multivariate Analysis
5%
Keyphrases
Attention-driven
33%
Topical Tranexamic Acid
33%
Stone Detection
33%
Helicobacter Pylori Treatment
33%
Infiltrative Hepatocellular Carcinoma
33%
Quadruple Regimen
33%
Sucralfate
33%
Antibiotic Selection
33%
Postpolypectomy
6%
Weakly Supervised Method
6%
